Alnylam slips 4.3% as investors digest Q1 results and unchanged full-year outlook

Alnylam Pharmaceuticals, Inc. (ALNY) is down 4.3% today. Here is some analysis on what might have caused this price movement.

Analysis: The move looks like a post-earnings pullback after the company’s Q1 update, with investors focusing less on the headline profitability improvement and more on expectations that were largely reiterated rather than raised. With ALNY already priced for strong TTR-franchise momentum, profit-taking and “sell-the-news” positioning could be amplifying the decline.

Details:

The company reported strong Q1 net product revenue (including a first quarter above $1 billion in product revenue), driven by continued growth of its TTR franchise led by AMVUTTRA.

Full-year 2026 net product revenue guidance was reiterated at $4.9 billion to $5.3 billion, which may have disappointed investors who were positioned for an upward revision after the strong quarter.

Management highlighted that collaboration/royalty comparisons are pressured by the non-recurrence of large prior-year milestone revenue, which can weigh on headline growth narratives even when product sales are accelerating.

This could also be a simple normalization after the sharp earnings-day reaction, as traders rebalance exposure following a high-volume event.

Sources:

Alnylam Investor Relations, U.S. SEC, Associated Press

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

$ALNY Insider Trading Activity

$ALNY insiders have traded $ALNY stock on the open market 273 times in the past 6 months. Of those trades, 0 have been purchases and 273 have been sales.

Here’s a breakdown of recent trading of $ALNY stock by insiders over the last 6 months:

YVONNE GREENSTREET (Chief Executive Officer) has made 0 purchases and 60 sales selling 51,917 shares for an estimated $20,420,981.
KEVIN JOSEPH FITZGERALD (CSO & EVP, Head of Research) has made 0 purchases and 66 sales selling 24,469 shares for an estimated $9,634,419.
PUSHKAL GARG (EVP Chief R&D) has made 0 purchases and 53 sales selling 16,584 shares for an estimated $5,431,156.
JEFFREY V. POULTON (EVP, Chief Financial Officer) has made 0 purchases and 40 sales selling 9,696 shares for an estimated $3,224,118.
TOLGA TANGULER (EVP, Chief Commercial Officer) has made 0 purchases and 40 sales selling 7,376 shares for an estimated $2,424,943.
MELISSA MCLAUGHLIN (Chief Human Resources Officer) has made 0 purchases and 14 sales selling 3,910 shares for an estimated $1,274,342.

To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API.

EARLY ACCESS

Receive ALNY Data Alerts

Real-time alerts on filings, insider trades, and market signals — before everyone else.

Get Alerts →

$ALNY Hedge Fund Activity

We have seen 417 institutional investors add shares of $ALNY stock to their portfolio, and 428 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

UBS AM, A DISTINCT BUSINESS UNIT OF UBS ASSET MANAGEMENT AMERICAS LLC removed 2,181,890 shares (-77.0%) from their portfolio in Q4 2025, for an estimated $867,628,558
REGENERON PHARMACEUTICALS, INC. removed 1,392,303 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $553,649,287
T. ROWE PRICE INVESTMENT MANAGEMENT, INC. removed 1,022,637 shares (-47.0%) from their portfolio in Q4 2025, for an estimated $406,651,603
FMR LLC removed 865,476 shares (-5.2%) from their portfolio in Q4 2025, for an estimated $344,156,531
BANK OF AMERICA CORP /DE/ removed 813,314 shares (-54.3%) from their portfolio in Q4 2025, for an estimated $323,414,312
INVESCO LTD. added 683,998 shares (+46.2%) to their portfolio in Q4 2025, for an estimated $271,991,804
JANE STREET GROUP, LLC removed 647,462 shares (-67.5%) from their portfolio in Q4 2025, for an estimated $257,463,264

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API.

$ALNY Analyst Ratings

Wall Street analysts have issued reports on $ALNY in the last several months. We have seen 5 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

Here are some recent analyst ratings:

B of A Securities issued a "Buy" rating on 01/30/2026
Barclays issued a "Overweight" rating on 01/28/2026
Needham issued a "Buy" rating on 01/12/2026
Truist Securities issued a "Buy" rating on 01/08/2026
Stifel issued a "Buy" rating on 12/11/2025

To track analyst ratings and price targets for $ALNY, check out Quiver Quantitative's $ALNY forecast page.

$ALNY Price Targets

Multiple analysts have issued price targets for $ALNY recently. We have seen 14 analysts offer price targets for $ALNY in the last 6 months, with a median target of $437.0.

Here are some recent targets:

Luca Issi from RBC Capital set a target price of $445.0 on 05/01/2026
Derek Archila from Wells Fargo set a target price of $377.0 on 05/01/2026
Danielle Brill from Truist Securities set a target price of $505.0 on 04/13/2026
Patrick R. Trucchio from HC Wainwright & Co. set a target price of $510.0 on 03/25/2026
Keay Nakae from Chardan Capital set a target price of $425.0 on 03/25/2026
Faisal Khurshid from Jefferies set a target price of $330.0 on 03/16/2026
Whitney Ijem from Canaccord Genuity set a target price of $429.0 on 02/17/2026

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.